MedPath
HSA Product

VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML

Product approved by Health Sciences Authority (SG)

Basic Information

VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML

INFUSION, SOLUTION CONCENTRATE

Regulatory Information

SIN16325P

September 16, 2021

Prescription Only

Therapeutic

INTRAVENOUS DRIP

August 10, 2023

June 3, 2025

XN02CD05

Company Information

LUNDBECK SINGAPORE PTE. LTD.

LUNDBECK SINGAPORE PTE. LTD.

Active Ingredients

EPTINEZUMAB

Strength: 100 MG/ML

Detailed Information

Contraindications

**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 3.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.

Indication Information

**4.1 Therapeutic indications** VYEPTI is indicated for prophylaxis of migraine in adults.

© Copyright 2025. All Rights Reserved by MedPath